Member Info for Deal3r

I suspect uptake has been very slow until they widened it out way from southampton. Probably filling up now. My guess it at 48 people so far.

Maybe trial a cheaper delivery system as well

So I hope to see some news out soon and it should flesh out details on a p3.

Does anyone have any thoughts on design and size?

I would think at will be at least three times of the data set so far, so upto 1000 patients. With a similar protocol as the p2. Multi centre, uk, us europe.

Do do so would require a partnership with a large pharma ( maybe) and run by a big third party.

Funding- some government funding wod be nice, but commercialized authorization would be nice.

Anyone else any thoughts.

Here are two articles of interest.

They may have already been posted.

https://www.bloomberg.com/news/articles/2020-09-24/covid-doctors-follow-dna-trail-to-potential-immune-treatment

https://www.theguardian.com/world/2020/sep/24/genetic-immune-defects-may-impair-ability-fight-covid-19

Congrats and best wishes to you and your family!!

Nice sentiment.

I now rarely post here.

I've been a holder since early January. I've tried to ignore the SP and wait for news. Investors abhor the vacuum of no news. The drop in SP is disappointing however I suspect some of the flighty pi have bailed along with the likes of lansdowne.

To me things are progressing fine and at a pace so will wait for substantive news and act. In the mean time I have topped up another 5k share earlier this morning.
I'm holding for further news.

Speaking. What works for you ...

I don't spend all day watching and worrying about the sp, I have work to do.

250k since January.

I bought for news on COPD, so I ignor the price and wait for results on that one way or another.
I only bought more when I'm in profit on my last purchase. I'll be driven by the news flow, if the next one is good and another RNS is expected I'll wait.

Delayed trades protect MM as they can unwind risk positions if they have taken on a large order. If not, MM will be unwilling to risk providing liquidity to the market and we all lose.

Hi and welcome-

You will tend to know if you are an insider - or you may be asked to come inside.

Your wife will have either an explicit rule that she can not buy stock or will be detailed in her employee handbook, but either way even if you work at Synairgen you may not be classed as an insider.

You may be in the lucky position of have more info or are just better informed..

Interactive Investor cover overseas markets : Australia, Belgium, Canada, France, Germany, Netherlands, Hong Kong, Ireland, Italy, Singapore,Spain and US.
They are OK-ish.

I not sure if this had been previously posted here as its now hard to keep track of what goes on here.

I read this article which give a range of expert views on the SNG001 trial results. Whilst it is encouraging it does give a flavour of some of the hesitations which some experts may have following release of the trial results.

https://www.sciencemediacentre.org/expert-reaction-to-announcement-by-synairgen-that-their-drug-sng001-has-had-positive-results-in-initial-trials-on-covid-19-patients/

B2...

Sorry, I hadn't seen your post. It's hard to keep track of the board these days.

This clearly speaks to the argument of acting early to avoid the wider health implications.

How long is a piece of string.

You are right as some say it could be off the charts but there are still risks along the way.

Morning Rich
Did you read this article
https://newatlas.com/health-wellbeing/heart-damage-recovered-covid19-patients-coronavirus/?itm_source=newatlas&itm_medium=most-viewed

Covid seem to damage the heart even if you weren't too I'll with it..

Still in 99%

or orders on the book drying up and the spread widening

Sounds too much like Sanatogen ??

Here are a couple links to the dosing question and is cited in SNG001 paper

https://academic.oup.com/jid/article/doi/10.1093/infdis/jiaa350/5860074#205049044

It does not state it in the presentation but I shall check the webinar.

https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-data-readout-final-version.pdf

Ta LimaLima

SNG001 is very exciting but we must be objective. There will be 1000s of other treatments being worked up. Our drug is very exciting and should be part of the picture but other drugs will play their part.

Don't get get too carried away and look at the evidence objectively.